Non-Squamous cell Non-small cell lung cancer MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
MDX-1106
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Trade Name: Taxotere 160 mg (20 mg/mL)
Product Name: Taxotere
Pharmaceutical Form: Conce
Sponsors
Bristol-Myers Squibb International Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Men & women = 18 years of age 2) Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease. 3) Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease 4) Measurable disease by CT/MRI per RECIST 1.1 criteria 5) ECOG performance status = 1 6) An FFPE tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient Specific eligibility criteria for subjects originally randomized to the docetaxel arm B and now entering the nivolumab Extension Phase are included in the protocol in Section 3.1.3. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 580
Exclusion criteria
Exclusion criteria: 1) Subjects with untreated CNS metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of =10mg daily prednisone (or equivalent) 2) Subjects with carcinomatous meningitis. 3) Subjects with active, known or suspected autoimmune disease. Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. 4) Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization. 5) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). 6) Prior treatment with docetaxel 7) Treatment with any investigational agent within 14 days of first administration of study treatment. Specific eligibility criteria for subjects originally randomized to the docetaxel arm B and now entering the nivolumab Extension Phase are included in the protocol in Section 3.1.3.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with non- squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy;Secondary Objective: 1. To compare the objective response rate (ORR) of BMS-936558 (nivolumab) to docetaxel 2. To compare progression-free survival (PFS) of BMS-936558 (nivolumab) to docetaxel 3. To evaluate whether PD-L1 expression is a predictive biomarker for OS and ORR 4. To evaluate the proportion of subjects exhibiting disease-related symptom improvement by 12 weeks, as measured by LCSS, in BMS-936558 (nivolumab) and docetaxel treatment groups;Primary end point(s): Overall Survival;Timepoint(s) of evaluation of this end point: 6, 12, 18, 24, 36, 48 months and 5 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. To compare the objective response rate (ORR) of BMS-936558 (nivolumab) to docetaxel 2. To compare progression-free survival (PFS) of BMS-936558 (nivolumab) to docetaxel 3. To evaluate whether PD-L1 expression is a predictive biomarker for OS and ORR 4. To evaluate the proportion of subjects exhibiting disease-related symptom improvement by 12 weeks, as measured by LCSS, in BMS-936558 (nivolumab) and docetaxel treatment groups;Timepoint(s) of evaluation of this end point: 6, 12, 18, 24, 36, 48 months and 5 year | — |
Countries
Argentina, Australia, Austria, Brazil, Canada, Chile, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Singapore, South Africa, Spain, Switzerland, Turkey, United States
Contacts
Public ContactGCT-SU
Bristol-Myers Squibb International Corporation
Outcome results
None listed